Fundraising Fox
Lapix Therapeutics
Boston, US · Founded 2019 · Delaware corporation
Find your way into Lapix Therapeutics
146 people in our graph share verified history with the Lapix Therapeutics team — schools, employers, funds. One of them is your warm intro.
Christopher Thanosunlockedknows Anas Fathallah · together at Halozyme Therapeutics, Inc. (overlapped)
×10knows the team · via Halozyme Therapeutics, Inc.
knows the team · via University at Buffalo
LAPIX Therapeutics is a clinical-stage biopharmaceutical company developing an orally administered, non-immunosuppressive T-cell engager therapy for people with autoimmune diseases. Its lead therapeutic, LPX-TI641, is an antigen-agnostic TIM pathway agonist targeting TIM-3 and TIM-4 receptors to restore immune balance across a range of autoimmune conditions.
Founders & leadership
AF
Anas FathallahCo-Founder and CEOAnas Fathallah is Co-Founder and CEO of LAPIX Therapeutics, a clinical-stage biopharmaceutical company developing orally administered T-cell engager therapies for autoimmune diseases. He has background experience as a drug developer and clinical pharmacologist with a track record of advancing programs from early discovery into clinical development.
Board
AG
Anthony GibneyBoard director
HM
Henry McKinnellBoard director
FL
Reported raises · per SEC filings
Form D private placements$14.9M disclosed across 4 rounds · 2022–2025
▶$2.2MraisedAug 2025 · 10 investors · Other TechnologyRule 506(b)
▶$2.2MraisedAug 2025 · 10 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Anas FathallahExecutive Officer, Director
- Anthony GibneyDirector
- Jason NorrisExecutive Officer, Director
- Francisco LeonDirector
- Henry McKinnellDirector
- Offering amount
- $5M
- Amount sold
- $2.2M
- Minimum investment
- $1K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedFeb 2025 · 25 investors · BiotechnologyRule 506(b)
▶$5.5MraisedFeb 2025 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Henry McKinnellDirector
- Anthony GibneyDirector
- Anas FathallahExecutive Officer, Director
- Jason NorrisExecutive Officer, Director
- Francisco LeonDirector
- Offering amount
- $6M
- Amount sold
- $5.5M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.9MraisedApr 2023 · 32 investors · BiotechnologyRule 506(b)
▶$5.9MraisedApr 2023 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason NorrisDirector
- Anas FathallahExecutive Officer, Director
- Offering amount
- $14.6M
- Amount sold
- $5.9M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.2MraisedOct 2022 · 7 investors · Other TechnologyRule 506(b)
▶$1.2MraisedOct 2022 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Anas FathallahExecutive Officer, Director
- Jason NorrisExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.2M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Robinhood14 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Lapix Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Lapix Therapeutics do?
- LAPIX Therapeutics is a clinical-stage biopharmaceutical company developing an orally administered, non-immunosuppressive T-cell engager therapy for people with autoimmune diseases. Its lead therapeutic, LPX-TI641, is an antigen-agnostic TIM pathway agonist targeting TIM-3 and TIM-4 receptors to restore immune balance across a range of autoimmune conditions.
- How much funding has Lapix Therapeutics raised?
- Lapix Therapeutics has disclosed $14.9M raised across 4 rounds.
- Where is Lapix Therapeutics headquartered?
- Lapix Therapeutics is headquartered in Boston, US.